摘要
为研制安全、有效的新型鸡毒支原体(MG)疫苗,本研究利用新城疫病毒(NDV)LaSota弱毒疫苗株反向遗传操作系统,构建出表达MG TM1蛋白的重组病毒rLa-TM1,并对其生物学特性进行鉴定,评估其作为MG活载体疫苗的安全性和有效性。通过免疫荧光试验表明TM1蛋白获得正确表达;经测定,重组病毒平均鸡胚致死时间(MDT)为132 h,脑内致死指数(ICPI)和静脉内致病指数(IVPI)均为0,保持了LaSota亲本株的低致病性;rLa-TM1接种鸡胚所收集尿囊液中的病毒滴度可高达每毫升109.5EID50以上,证明重组病毒保持了LaSota亲本株高滴度鸡胚生长特性;重组病毒rLa-TM1接种1周龄的雏鸡后,可以诱导显著的MG抗体反应;攻毒保护试验证明其保护率可以达90%,而对照组全部发病(10/10)。本研究表明重组病毒rLa-TM1可以作为MG重组病毒活载体疫苗的候选疫苗。
In order to develop a safe and efficient recombinant Mycoplasma gallisepticum （MG） vaccine based on Newcastle disease virus （NDV） LaSota vaccine strain as viral vector, we constructed and rescued a recombinant NDV （rLa-TM1） which expressed TM1 protein of MG by reverse genetic techniques. The expression of MG TM1 protein from recombinant virus was confirmed in the infected BHK cells by indirect immunofluorescence assay. Pathogenic test shown that the rLa-TMI retained NDV high-titer growth property and low pathogenicity in embryonated chicken eggs. Moreover, the rLa-TM1 induced high titer of antibody against MG in one week post vaccination in chickens which provided up to 90% of protection against MG challenge. These results demonstrated that the rLa-TM1 had the potential of being used as a novel MG vaccine.
出处
《中国预防兽医学报》
CAS
CSCD
北大核心
2013年第10期779-782,共4页
Chinese Journal of Preventive Veterinary Medicine
基金
国家自然科学基金(30800816)
